Article Text

Download PDFPDF
Rare disease
Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease
  1. Mubashira Hashmi1,
  2. Feroza Saleem2,
  3. Muhammad Shahid Mustafa1,
  4. Mughis Sheerani1,
  5. Zeeshan Ehtesham3,
  6. Khurram Siddiqui4
  1. 1Department of Neurology, Aga Khan University Hospital, Karachi, Pakistan
  2. 2Department of Neurology, Liaquat National Hospital, Karachi, Pakistan
  3. 3Department of Pathology, Aga Khan University Hospital, Karachi, Pakistan
  4. 4Department of Neurology, King Fahad Medical City, Riyadh, Saudi Arabia
  1. Correspondence to Mubashira Hashmi, dr_mhashmi{at}


Lafora disease is one of the rare, most fatal progressive myoclonic epilepsies reported. We present a case of a teenager with intractable seizures and progressive mental decline, diagnosed as Lafora body disease on axillary skin biopsy. He was admitted with status epilepticus with refractory myoclonic and generalised tonic clonic seizures. Despite on maximum doses of multiple antiepileptic drugs and infusions of propofol and midazolam, his seizures were refractory to all forms of medical therapy tried. Levetiracetam (LEV), a pyrrolidine derivative, was introduced; he showed a prompt response and was weaned off successfully from infusions of anticonvulsants and mechanical ventilation within 48 h of introduction of LEV, followed by an almost seizure-free status.

View Full Text

Statistics from


  • Competing interests None.

  • Patient consent Not obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.